Wednesday, March 8, 2023 Daily Archives

GenSight gene therapy delay due to operation issue at CDMO Thermo Fisher

by

Share price dropped 32% after GenSight Biologics pushed back proposed regulatory dates because of an undefined operational issue at CDMO Brammer Bio, a subsidiary of Thermo Fisher. Lumevoq (lenadogene nolparvovec) is an intravitreal adeno-associated virus (AAV) gene therapy being developed by GenSight to treat vision loss disease Leber hereditary optic neuropathy (LHON). GenSight had earmarked September 2023 for the possible approval of the late-stage therapy in Europe but has pushed this back to the first quarter 2024 following a production…

March 8, 2023

Adaptimmune merges with TCR² Therapeutics

by

The stock for stock transaction will see Adaptimmune shareholders own 75% of the combined company, which will target solid tumors. The deal, which is expected to close in the second quarter of 2023,  sees Adaptimmune and TCR² Therapeutics merge to create a cell therapy company for solid tumors through the use of their respective technology platforms. “This strategic combination brings together two culturally aligned companies at the forefront of the field to create a preeminent cell therapy company for solid…

March 8, 2023

Voices of Biotech: Bayer on why female role models matter

by

“Women and people of diverse backgrounds remain underrepresented in the upper echelons of the biopharma C-suite,” says Ilona Gutcher, director of BD&L Oncology at Bayer. Aligning with International Women’s Day (Wednesday 8th March) the BioProcess Insider Expression Platform has released its second episode of Voices of Biotech. “I wouldn’t be here without the I&D Xcelerate program,” says Gutcher, another graduate of the Bayer program launched by Marianne De backer two years ago to promote diversity through a 6–9 month placement…

March 8, 2023